CAMBRIDGE, Mass.–(BUSINESS WIRE)–Today, we announce that on February 15, 2017, KEW, Inc., a privately-held molecular diagnostics company located in Cambridge, MA, USA and Denka, Co., Ltd. , a commercial manufacturing company of chemical and life science products, located in Tokyo, Japan, officially entered into a joint venture, Denka-KEW Genomics LLC (“DKGX”), for the purposes of providing comprehensive genomic profiling to cancer patients in Japan and guiding therapeutic decisions based on individual patient tumor profiles.
“In October, 2015, KEW and Denka announced a strategic collaboration to establish the feasibility of using CANCERPLEX in Japanese patients. Our recent publication in Genome Medicine (2016) is the culmination of these efforts and serves as the basis for our establishing DKGX,” said Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School and co-founder of KEW, Inc.
“The formation of DKGX represents a key milestone toward helping cancer patients in Japan. KEW is honored to partner with Denka in this important mission,” said Tuan Ha-Ngoc, Executive Chairman, KEW, Inc.
In the first half of 2017, DKGX will open a commercial clinical comprehensive genomic profiling laboratory in Machida City, Tokyo. Under terms of the agreement, KEW will license its CANCERPLEX® sequencing platform to DKGX. Additional terms of the agreement are not disclosed at this time.
CANCERPLEX® is a comprehensive genomic profiling platform for sequencing over 400 cancer-related genes, providing treatment decision support for cancer patients based on a patient’s tumor genomic profile. Using industry-leading sequencing approaches and robust data analytics, a sample acceptance rate of >95% and a rapid turn-around time of 7-10 business days, CANCERPLEX® provides therapeutic options to >90% cancer patients profiled.
About Denka-KEW Genomics
Nihonbashi Mitsui Tower, 1-1, Nihonbashi-Muromachi
2-chome, Chuo-ku,Tokyo 103-8338, JAPAN
5-1, Asahi-machi 3-chome, Machida-shi, Tokyo 194-8560, JAPAN
|Paid-in Capital||10 million JPY|
|Capital contribution ratio||Denka 55% KEW 45%|
|Business Launch||April 2017|
About KEW, Inc.
KEW, Inc. is a privately-held comprehensive genomic profiling company with headquarters in Cambridge, MA, USA., dedicated to revolutionizing cancer care by providing therapeutic options based on an individual patient’s tumor genomic profile. CANCERPLEX® is KEW’s flagship clinical product family for sequencing and identifying applicable targeted therapies and clinical trials.
About Denka, Co. Ltd.
Denka Co. Ltd., is a public manufacturing and distribution company for a variety of chemical products, including organic and inorganic materials, polymers, electronic materials and pharmaceuticals, contributing to the quality of life and development of society for 100 years through innovations in technology. Focusing on healthcare business sector as a key growth area, Denka is establishing its fifth business division, “Life Innovation”, to accelerate its growth.